


Showcasing research from Professor Varghese's laboratory, School of Chemistry, Indian Institute of Science Education and Research (IISER), Thiruvananthapuram, Trivandrum, India.

Tumor microenvironment responsive nanocarriers for efficient antisense DNA delivery and enhanced chemodynamic therapy

A supramolecular strategy for the design of multifunctional tumour microenvironment sensitive nanoparticles composed of artemisinin, ferrocene and antisense DNA *via* a single-step assembly process is demonstrated. Enhanced therapeutic efficacy was observed due to the cooperative cascade CDT and antisense therapy.

As featured in:



See Reji Varghese *et al.*,
Mater. Chem. Front., 2023, 7, 1821.

RESEARCH ARTICLE

View Article Online
View Journal | View IssueCite this: *Mater. Chem. Front.*,
2023, 7, 1821

Tumor microenvironment responsive nanocarriers for efficient antisense DNA delivery and enhanced chemodynamic therapy†

Gowtham Raj,^a Vasudev D. S.,^a Nikhil Dev Narendradev,^b
Viswa Kalyan Kumar Dommeti,^a Saurabh Shriwas,^a P. M. Ajay Sekhar,^a
Leah Susan Jacob,^b S. Murty Srinivasula^b and Reji Varghese^b*

Cancer is undoubtedly one of the major threats to mankind. Herein, we demonstrate a supramolecular approach for the design of tumour microenvironment sensitive nanoparticles composed of artemisinin, glutathione-responsive and redox-active ferrocene and antisense DNA via a single-step assembly. Assembly between the antisense DNA and ferrocene derivative results in the noncovalent tethering of the latter along the backbone of antisense DNA and leads to the formation of the corresponding supramolecular amphiphile. The addition of hydrophobic artemisinin during the assembly of the supramolecular amphiphile permits the encapsulation of artemisinin and leads to the formation of glutathione-responsive NPs composed of antisense DNA, ferrocene derivative and artemisinin. The most remarkable feature of our design strategy is the glutathione-triggered cascade reactions of the NPs inside the cancer cell in a cooperative fashion. Cleavage of disulfide bonds of the NPs by the overexpressed glutathione in the tumour microenvironment leads to the following cascade chemodynamic therapy reactions: (i) glutathione-triggered uncaging of the ferrocene derivative to release amino ferrocene, which then undergoes reaction with endogenous hydrogen peroxide to produce $\cdot\text{OH}$ radicals and Fe^{3+} and (ii) the *in situ* reduction of Fe^{3+} by glutathione to form Fe^{2+} and the subsequent Fe^{2+} -triggered cleavage of the peroxide bond of artemisinin to form carbon-centered free radicals. Furthermore, disassembly of NPs releases antisense DNA, which efficiently downregulates the translation of Bcl-2 mRNA and thereby causes cell apoptosis. Excellent anticancer efficacy is demonstrated by using HeLa cells as a representative example and the enhanced therapeutic efficacy of our approach is attributed to the co-operative cascade CDT and antisense therapy.

Received 19th January 2023,
Accepted 17th March 2023

DOI: 10.1039/d3qm00073g

rsc.li/frontiers-materials

Introduction

Cancer is undoubtedly one of the major causes of death to mankind. Recent years have witnessed the emergence of chemodynamic therapy (CDT) as a powerful strategy for the treatment of cancer.^{1,2} Chemodynamic therapy relies on the generation of highly cytotoxic reactive oxygen species (ROS) through Fenton or Fenton-like reactions by exploring the endogenous H_2O_2 present inside the cancer cells.^{3–5} Typically, CDT involves the delivery of a suitable Fenton catalyst into the cancer cells, which catalyses the conversion of endogenous

H_2O_2 present inside the cells to the cytotoxic ROS that causes oxidative damage to DNA, proteins and lipids, which eventually leads to cell death. Even though the concentration of endogenous H_2O_2 inside the cancer cells (50–100 μM) is significantly higher when compared to healthy cells, it is still insufficient to perform an efficient Fenton reaction and hence traditional CDT suffers from poor therapeutic efficacy. One way to address this challenge is through the direct delivery of H_2O_2 and Fenton catalyst to the cancer cell by using a nanocarrier. Alternatively, the intratumoral H_2O_2 level can be boosted by delivering H_2O_2 generating natural enzymes such as glucose oxidase,^{6,7} or nicotinamide adenine dinucleotide phosphate oxidase.^{8,9} Though significant improvements have been achieved by using these strategies, the therapeutic efficacy of these approaches is not impressive for clinical applications. Therefore, the development of novel strategies that permit the elevation of the intratumoral H_2O_2 level is extremely important for effective CDT.^{10–16}

^a School of Chemistry, Indian Institute of Science Education and Research (IISER), Thiruvananthapuram, Trivandrum-695551, Kerala, India.

E-mail: reji@iisertvm.ac.in

^b School of Biology, Indian Institute of Science Education and Research (IISER), Thiruvananthapuram, Trivandrum-695551, Kerala, India† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3qm00073g>

To overcome the above-mentioned challenges, an ideal strategy would be the design of nanoagents that generate ROS in an H_2O_2 independent pathway in addition to the hydroxyl radicals generated by conventional CDT so that the overall efficacy of CDT can be significantly improved. This is typically achieved by delivering any peroxide linkage containing molecule into the cancer cell, which undergoes peroxide cleavage in the presence of metal ions (Fe^{2+}) and increases the radical species inside the cells and leads to cell apoptosis.¹⁷ Artemisinin (**ART**), a popular antimalarial drug, is an organic molecule having an endoperoxide bridge and has recently been identified as a potential anticancer agent.¹⁸ Though various factors are responsible for its anticancer activity, the generation of cytotoxic carbon-centered free radicals by Fe^{2+} -catalysed cleavage of the peroxide bond of **ART** is proven to be the major cause of its activity.^{19–21} This suggests that **ART** could be a potential candidate as a peroxide containing molecule that can generate cytotoxic radical species in Fe^{2+} -catalysed reaction and hence would be a promising molecule for CDT. Two major hurdles that limit the scope of **ART** for CDT applications are (i) poor water solubility of **ART** and (ii) lack of control over the delivery of **ART** and the metal ions. The poor water solubility of **ART** can be addressed to a large extent by the use of a suitable nanocarrier as the delivery vehicle, but the controlled delivery of **ART** and metal ions into the cancer cell remains challenging. Furthermore, the lack of adequate concentration of Fe^{2+} inside the cancer cell is another obstacle for the therapeutic efficacy of CDT. Hence, the design of nanocarriers that permit the tumour microenvironment-triggered co-delivery of **ART** and Fe^{2+} in a controlled fashion would be the ideal approach for an efficient CDT.

Nanostructures derived from DNA have received enormous attention in recent years as a stimuli-responsive delivery vehicle for various biomedical applications.^{22–25} This is mainly due to their remarkable structural and functional characteristics including (i) excellent biocompatibility, (ii) stimuli responsive nature, (iii) enhanced cell permeability and (iv) high resistance to enzymatic degradation.^{26–32} In addition, an anionic phosphodiester backbone or the nucleobases of DNA can act as a ligand for the coordination of various metal ions, which has been extensively applied for the crafting of DNA-metal condensates and for the development of various anticancer drugs.³³ Metal bound DNA NPs have also been explored as responsive nanoagents for CDT, which showed enhanced generation of ROS.^{34,35} Since this approach involves the direct binding of metal ions onto the anionic backbone of DNA by means of strong electrostatic interactions, these systems lack stimuli-responsiveness for the disassembly of NPs inside the cancer cell. Moreover, this approach may damage the functional properties of DNA by the reaction with the *in situ* generated radicals and potentially reduce the therapeutic efficacy of functional DNA.


Herein, we report a novel supramolecular strategy for the design of tumour microenvironment sensitive DNA nanoparticles (NPs) composed of **ART**, glutathione (GSH) responsive and redox-active ferrocene (**1**) and antisense DNA (**DNA1**) via a single-step assembly, guided mainly by electrostatic interactions.

The redox-active ferrocene **1** is functionalized with an ammonium group at the end of the alkyl chain through a GSH responsive disulfide bond. Assembly between the antisense DNA (**DNA1**) and **1** results in the noncovalent tethering of **1** along the anionic backbone of **DNA1** and leads to the formation of supramolecular amphiphile, **DNA1@1**. The addition of hydrophobic **ART** during the assembly of **DNA1@1** permits the encapsulation of **ART** inside the hydrophobic pockets of **DNA1@1** and leads to the formation of GSH-responsive **DNA1@1-ART** NPs. The presence of a disulfide bond in the NPs not only permits their GSH-triggered disassembly inside the cancer cell, but also helps to deplete the GSH concentration, which is advantageous for efficient CDT. In addition, a disulfide bond keeps the ferrocene in a caged state (prodrug) and the GSH-triggered uncaging of ferrocene leads to the generation of ROS, which makes DNA less susceptible to oxidative damage caused by the *in situ* radicals.^{36,37} The most remarkable feature of our design strategy is the GSH-triggered cascade reactions of the NPs inside the cancer cell in a cooperative fashion for synergistic cancer therapy. Cleavage of disulfide bonds of **DNA1@1-ART** NPs by the overexpressed GSH in the tumour microenvironment leads to the following cascade CDT reactions: (i) GSH-triggered uncaging of **1** releases amino ferrocene, which then undergoes reaction with endogenous H_2O_2 to produce $\bullet\text{OH}$ radicals and Fe^{3+} and (ii) the *in situ* reduction of Fe^{3+} by GSH to form Fe^{2+} and the subsequent Fe^{2+} -triggered cleavage of the peroxide bond of **ART** to form carbon-centered free radicals (H_2O_2 independent pathway). Furthermore, disassembly of **DNA1@1-ART** NPs releases **DNA1**, which is an 18 mer oligonucleotide complementary to the first six codons of Bcl-2 (anti-apoptotic) mRNA, which efficiently downregulates the translation of Bcl-2 mRNA (anti-apoptotic) and thereby causes cell apoptosis. Excellent anticancer efficacy is demonstrated by using HeLa cells as a representative example and the enhanced therapeutic efficacy of our approach is attributed to the cooperative cascade CDT and antisense therapy (Scheme 1).

Results and discussion

Synthesis of cationic ferrocene probe **1** was achieved through multistep organic reactions and the details are provided in the ESI† **DNA1** is an 18-mer antisense DNA (G3139), which was synthesized on a DNA synthesizer using standard protocols. Sequences of all DNAs used in our study are tabulated in Table 1. In a typical procedure, synthesis of **DNA1@1** and **DNA1@1-ART** NPs was achieved by annealing a 20:1 molar ratio of cationic ferrocene probe **1** (2 μM) and **DNA1** (0.1 μM) in deionized water at 90 °C for 10 minutes followed by slow cooling to room temperature at a cooling rate of 5 °C min^{-1} . The molar ratio of 20:1 was used in our studies after confirming that the NP formation was complete only at this molar ratio. A molar ratio of **1** less than 20 always leads to incomplete formation of the NPs (Fig. S1, ESI†). During the annealing process, **ART** was added to the solution at 60 °C for the synthesis of **DNA1@1-ART** NPs. After aging this solution for an additional 12 h, **DNA1@1** or **DNA1@1-ART** aggregated





Scheme 1 Schematic representation depicting the formation of a **DNA1@1** supramolecular amphiphile by the noncovalent tethering of **1** along **DNA1** and its subsequent amphiphilicity-driven self-assembly in the presence of **ART** to the formation of **DNA1@1-ART** NPs. The cellular internalization of **DNA1@1-ART** NPs followed by the GSH-triggered cascade reactions leading to the release of antisense DNA (**DNA1**), $\bullet\text{OH}$ and carbon-centered radicals through Fenton and Fenton-like reaction for synergistic cancer therapy are also shown.

Table 1 Sequence of DNAs

DNA	Sequence (5' → 3')
DNA1	TCT CCC AGC GTG CGC CAT
DNA2	Cy3.5-TCT CCC AGC GTG CGC CAT
DNA3	TCT CCC AGG CTG GCC CAT

species were centrifuged using a molecular weight cut-off filter at a speed of 4000 rpm for 10 min in order to remove any unbound **ART** or **1** from the solution. Atomic force (AFM) and transmission electron (TEM) microscopic analyses revealed the formation of spherical NPs for **DNA1@1** aggregates (Fig. 1a and b), respectively. Nanoparticle formation was further supported by confocal laser scanning microscopic (CLSM) analyses by using Cy3.5 labelled **DNA1** (**DNA2**), which showed the formation of fluorescent NPs (green, **DNA2@1**) (Fig. 1c). Dynamic light scattering (DLS) analyses of **DNA1@1** aggregates confirmed the formation of spherical NPs in solution with an average diameter of ~ 150 nm (Fig. 1d). It is to be noted that though **1** is amphiphilic in nature, self-assembly of **1** in the absence of **DNA1** resulted only in the formation of ill-defined aggregates, disclosing the unique role of DNA as a template in controlling the morphology of the aggregated species (Fig. S1 and S2, ESI[†]). The encapsulation of **ART** was confirmed by comparing the absorption spectrum of free **ART** with the corresponding **DNA1@1-ART** NPs. A strong absorption band centred at 290 nm was observed for free **ART** (5 μM in DMSO) containing NaOH in water (50 mM). Whereas, no noticeable absorption was observed for the filtrate obtained after centrifuging **DNA1@1-ART** NPs using a molecular weight cut off filter, clearly indicating the efficient encapsulation of **ART** inside the NPs (Fig. 1e). The loading efficiency of **ART** was calculated to be 80% (Fig. S3, ESI[†]). Moreover, no significant change in the size of the




Fig. 1 (a) AFM and (b) TEM images of **DNA1@1** NPs. (c) CLSM image of **DNA2@1** NPs and (d) DLS analysis of **DNA1@1** NPs. (e) Comparison of absorption spectra of free **ART** and **DNA1@1-ART** NPs. (f) Comparison of zeta potential values of **1**, **DNA1** and **DNA1@1** NPs. Experiments were performed in triplicate and repeated three times with similar results.

NPs was observed before and after **ART** encapsulation (Fig. S5, ESI[†]). Energy-dispersive X-ray spectroscopy (EDS) analyses of **DNA1@1** NPs revealed the presence of iron and sulfur from **1**, and phosphorous from **DNA1** (Fig. S4a, ESI[†]). The zeta potential measurement of **DNA1@1** NPs showed a value of -1.46 mV, whereas **DNA1** and **1** exhibited values of -9.72 and $+9.64$ mV, respectively. The almost neutral zeta potential value for **DNA1@1** is indicative of the formation of **DNA1@1** NPs (Fig. 1f). The X-ray photoelectron spectroscopy (XPS) analyses of **DNA1@1** NPs revealed peaks at 710.0 and 723.6 eV, which is due to the presence of Fe(II) 2p_{3/2} and Fe(II) 2p_{1/2} ions, respectively (Fig. S4b, ESI[†]). Based on these results, the formation of NPs can be envisaged to be the initial formation of supramolecular amphiphile **DNA1@1** by the non-covalent tethering of **1** along the anionic backbone of **DNA1** and the subsequent amphiphilicity-driven self-assembly of **DNA1@1** leads to the formation of **DNA1@1** NPs and in the presence of hydrophobic **ART** self-assembly results in the formation of **ART** encapsulated NPs (**DNA1@1-ART** NPs).

After confirming the nanoparticle formation for **DNA1@1** and **DNA1@1-ART**, we initially studied the $\bullet\text{OH}$ radical generation by **DNA1@1** NPs. This was investigated by using a methylene blue degradation assay by monitoring the absorption changes of the dye at 665 nm. As expected, when H_2O_2 (10 mM) alone was added to the mixture of **DNA1@1** NPs (100 μM) and methylene blue (15 μM), no decrease of absorbance of the dye at 665 nm was observed, indicating the lack of generation of $\bullet\text{OH}$ radicals (Fig. 2a). As designed, this clearly suggests that GSH-triggered cleavage of the disulfide bond of **1** is the first and triggering step for the production of $\bullet\text{OH}$. Accordingly, significant decreases in absorbance of the dye at 665 nm were observed when **DNA1@1** NPs were treated with H_2O_2 (100 μM) and GSH (0.5 mM). This can be attributed to the initial cleavage of the disulfide bond of the prodrug **1** by the reaction with GSH, leading to the release of reactive amino ferrocene, which in-turn undergoes redox reaction with H_2O_2 and produces $\bullet\text{OH}$. This causes the degradation of methylene blue and decreases the absorbance of the dye at 665 nm. A time-






Fig. 2 (a) Comparison of the absorption spectra of MB in the presence of different stimuli such as H₂O₂ (blue graph), H₂O₂ + DNA1@1 NPs (purple graph) and H₂O₂ + GSH + DNA1@1 NPs (black graph). (b) EPR spectrum of DNA1@1 NPs in the presence of 100 mM DMPO, 8 mM H₂O₂ and 0.5 mM GSH in dibasic sodium phosphate-citric acid buffer. (c) Reaction scheme depicting the formation of a red coloured [Fe(bipy)₃]²⁺ complex and the corresponding visual colour changes of the DNA1@1 NPs solution with the addition of H₂O₂ and H₂O₂ in the presence of GSH. (d) Comparison of quantification of Fe³⁺ release from DNA1@1 NPs with addition of H₂O₂ and H₂O₂ in the presence of GSH. Experiments were performed in triplicate and repeated three times with similar results.

dependent methylene blue degradation assay showed that 35% degradation of the dye occurs at ~6 h of incubation (Fig. S5, ESI†). These observations are in full accordance with our design. The catalytic activity of the NPs was found to increase with the decrease of the pH and the optimum pH was found to be 4.5 (Fig. S9, ESI†). Furthermore, the catalytic activity of the DNA1@1 NPs showed dose-dependent enhancement in a methylene blue degradation assay with respect to an increase in H₂O₂ concentration (Fig. S10, ESI†). DNA1@1 NPs also showed enhanced catalytic activity at high intracellular GSH concentration of ~0.5 mM when compared to low extracellular GSH concentration of ~2 μM (Fig. S11, ESI†). The formation of •OH was further confirmed by electron paramagnetic resonance (EPR) analyses of GSH and H₂O₂-treated DNA1@1 NPs at pH 5.5, which exhibited the characteristic 1 : 2 : 2 : 1 spectrum of •OH with hyperfine coupling constants of aN = 14.9 G and aH = 14.9 G, as reported (Fig. 2b).³⁸ Furthermore, the free Fe³⁺ ions formed from amino ferrocene, one of the products of the Fenton reaction, were detected using a chromogenic reaction with 2,2'-bipyridine (bipy) (300 μM). This was achieved by reducing Fe³⁺ to Fe²⁺ by using sodium dithionite, and the *in situ* formed Fe²⁺ was then trapped by complexing with bipy, which forms a red coloured [Fe(bipy)₃]²⁺ complex. Accordingly, red coloured [Fe(bipy)₃]²⁺ complex formation was observed for GSH and H₂O₂ treated-DNA1@1 NPs, whereas no complex formation was observed for H₂O₂ alone treated-DNA1@1 NPs (Fig. 2c). The release efficiency of Fe³⁺ was calculated to be 42% for GSH and H₂O₂ treated-DNA1@1 NPs, whereas only negligible release of Fe³⁺ (4%) was observed for H₂O₂ alone treated-DNA1@1 NPs (Fig. 2d). This further supports our hypothesis that GSH-triggered disassembly of DNA1@1 NPs is indeed

responsible for the Fenton reaction and the subsequent release of Fe³⁺. In addition, GSH-triggered disassembly of DNA1@1 NPs was further characterized by monitoring the release of DNA1 (Fig. S12, ESI†). As expected, no gel electrophoretic mobility was observed for DNA1@1 NPs. Interestingly, GSH-treated DNA1@1 NPs showed a band with electrophoretic mobility comparable to free DNA1, which can be attributed to the DNA1 released from the NPs after its disassembly. The decreased mobility observed can be attributed to the electrostatic association of the ammonium salt of ethyl thiol (obtained after GSH reaction of 1) onto the DNA1 backbone.

We then investigated the reactivity of the probe 1 towards GSH, which was studied by monitoring the reaction of GSH with 5,5'-dithiobis[2-nitrobenzoic acid] (DTNB) in the presence and absence of 1. Reaction of GSH with DTNB is known to produce the chromogenic molecule, 2-nitro-5-thiobenzoic acid with distinct spectral features. The absorption maximum of DTNB undergoes bathochromic shift from 320 to 410 nm upon reaction with GSH. Accordingly, a decrease of the absorption band at 320 nm with the concomitant increase of the absorption band at 410 nm was observed with the addition of GSH to DTNB and was attributed to the formation of 2-nitro-5-thiobenzoic acid (Fig. 3a). In a separate experiment, GSH was incubated with probe 1 for 6 h, centrifuged and the supernatant was mixed with DTNB and the absorption spectrum of the supernatant was recorded. A comparison of the absorption spectra of the supernatant with the corresponding solution without 1 revealed a significant reduction of the intensity of the peak of 2-nitro-5-thiobenzoic acid at 400 nm. This clearly indicates that 1 undergoes an efficient reaction with GSH and as a consequence of this reaction, no significant amount of GSH was available for the subsequent reaction with DTNB. This clearly shows the high reactivity of 1 towards GSH as designed.

After confirming the H₂O₂-mediated formation of •OH and GSH-directed cleavage of the disulfide bond of 1, we then investigated the generation of carbon centered radical species *via* a H₂O₂-independent pathway, that is, by the reaction between ART and Fe²⁺. The formation of carbon centered radical species was monitored by using 1,3-diphenylisobenzofuran (DPBF) as the probe. The dye, DPBF, has its characteristic absorption band centered at 410 nm, and the oxidation of the dye by the *in situ* generated carbon centered




Fig. 3 (a) Comparison of the UV-vis absorption spectra of 1 (black trace), DTNB (blue), GSH (dark blue), DTNB and 1 (green), DTNB and GSH (grey) and DTNB, GSH and 1 (red). (b) Time-dependent absorption spectra of DPBF in the presence of Fe²⁺ and ART.



radical species causes the decrease of the characteristic absorption band at 410 nm. This is typically used for the characterization of radical species in solution.³⁹ For this purpose, **ART** was treated with Fe^{2+} ($\text{FeCl}_2 \cdot 4\text{H}_2\text{O}$) in the presence of DPBF in ethanol and the absorption of DPBF at 410 nm was monitored with time. As shown in Fig. 3b, a gradual decrease in the absorption of DPBF was observed with time, indicating the oxidation of DPBF by the reaction with the *in situ* generated carbon centered radical species. As expected, no decrease in the absorption of DPBF was observed when it was treated just with **ART** (Fig. S6, ESI[†]). This clearly proves our hypothesis that Fenton-like reaction between **ART** and Fe^{2+} efficiently generates radical species in an H_2O_2 independent pathway for the synergetic CDT.

After the characterization of NPs and its responsive behaviours with respect to various stimuli, we then investigated the internalization of the NPs into cancerous cells. For this purpose, HeLa cells were taken as a representative cell line and were incubated with **DNA2@1** NPs for 6 h. Control experiments were also performed with free **DNA2** as well. CLSM images (Fig. 4a) showed strong fluorescence for **DNA2@1** NP-treated cell lines (red fluorescence) when compared to the corresponding free **DNA2**-treated cells (Fig. 4b). This validates the efficient internalization of **DNA2@1** NPs into HeLa cells, whereas no internalization was observed for **DNA2**-treated cells, as expected. Furthermore, time-dependent CLSM analyses showed that the internalization of **DNA2@1** NPs into the HeLa cells occurs within 3 h of incubation (Fig. S7, ESI[†]). On the other hand, no internalization was observed for **DNA2**-treated cells even after 6 h of incubation (Fig. 4b). These observations were further quantified using fluorescence activated cell sorting (FACS) analyses (Fig. 4c and d). In support of CLSM observations, high mean fluorescence intensity (MFI) shift was associated with **DNA2@1**-treated HeLa cells (24450) when compared with the MFI shift (265) of **DNA2**-treated cells. Collectively, CLSM and

FACS analyses conclude the efficient internalization of **DNA2@1** NPs into the HeLa cells and the NPs are mainly distributed in the cytoplasm.

Because **DNA2@1** NPs contain disulfide bonds (from **1**), the internalization of the NPs may occur through a thiol-mediated uptake pathway. To shed more light on the internalization pathway of the NPs, we next investigated whether **DNA2@1** NPs enter into the HeLa cells through the endocytotic pathway or thiol-mediated uptake. Towards this end, HeLa cells were initially treated with endocytosis inhibitor, methyl- β -cyclodextrin ($\text{M}\beta\text{CD}$, 50 μM), which is known to efficiently block the endocytosis pathway. Interestingly, endocytosis inhibitor $\text{M}\beta\text{CD}$ showed remarkable influence on the cellular uptake efficiency of **DNA2@1** NPs (red) and no significant uptake of **DNA2@1** NPs was observed as evident from the CLSM analyses (Fig. 5a). On the other hand, 5,5'-dithiobis-2-nitrobenzoic acid (DTNB), which is a known exofacial thiol blocking agent, had no notable effect on the uptake of **DNA2@1** NPs. These results rule out the possibility of thiol-mediated uptake of the NPs and **DNA2@1** NPs enter into the HeLa cell solely through the endocytosis pathway. In support of this, the uptake efficiency of **DNA2@1** NPs was found to be significantly reduced when the cells were pre-treated at 4 $^\circ\text{C}$, as endocytosis is a temperature-dependent process. These observations were further quantified using FACS analyses, which revealed mean fluorescence intensity (MFI) shifts of 2800, 2604, 1844 and 177 for untreated cells, DTNB-treated cells, $\text{M}\beta\text{CD}$ -treated cells and pre-treated cells at 4 $^\circ\text{C}$, respectively (Fig. S15, ESI[†]). In order to get better insight into the location of the NPs after their cellular entry, various colocalization experiments were performed. For this, lysosomes of HeLa cells were stained with LysoTracker deep red (LysoTracker, red fluorescence). Merged CLSM analyses obviously revealed no colocalization of green fluorescence of **DNA2@1** NPs and the red fluorescence of LysoTracker, suggesting that the NPs escape from the lysosomes, as reported in similar examples (Fig. 5b). The extent of colocalization of **DNA2@1** NPs and lysosome was quantified by using Pearson's correlation coefficient and the value was found to be 0.035. This value is significantly lower compared to the threshold value (>0.5) required for a correlation. These results conclude that **DNA2@1** NPs enter the cancer cell through endocytosis, undergo lysosomal escape and are distributed mainly in the cytosol.

It is known that the lysosomal compartment of cancer cells is highly sensitive to oxidative damage caused by the radical species. After the cellular entry, the NPs undergo disassembly due to the presence of GSH and H_2O_2 followed by the *in situ* generation of ROS and carbon centered radical species, which can potentially damage the lysosome membrane. In order to check whether any damage occurs to the lysosome membrane due to the disassembly of the NPs (**DNA1@1-ART** NPs), an Acridine Orange staining assay was carried out. For this, HeLa cells were initially stained with Acridine Orange and the red fluorescence of Acridine Orange was monitored using CLSM, which is an indicator of acidic regions inside the cells including lysosomes. If the lysosomal membrane is damaged or the lysosome itself is being disrupted, an increase in pH inside




Fig. 4 (a) CLSM images of **DNA2@1** NPs-treated HeLa cells and (b) the corresponding FACS analysis after 6 h of incubation. (c) Time-dependent CLSM images of **DNA2**-treated HeLa cells and (d) the corresponding FACS analyses. The incubation time for FACS is 6 h.






Fig. 5 (a) CLSM images of **DNA2@1** NP-treated HeLa cells (red fluorescence) in the presence of different inhibitors; DTNB (4.8 mM), M β CD (50 μ M), and after pre-treatment at 4 $^{\circ}$ C. The nucleus of the cells was stained with Hoechst (blue fluorescence) to monitor the colocalization of **DNA2@1** NPs. (b) CLSM images of **DNA2@1** NP-treated HeLa cells with lysosomes stained with Lysotracker deep red. (c) CLSM images of **DNA1@1-ART** NP-treated HeLa cells with the nucleus (green fluorescence) and lysosomes (red fluorescence) stained with Acridine Orange. (d) CLSM images of **DNA2@1** NP-treated HeLa cells (green fluorescence) with the mitochondria stained with MitoTracker (red fluorescence). (e) CLSM images of **DNA2@1** NP-treated HeLa cells with TMRM stain.

the lysosome and hence a decrease in fluorescence intensity was expected. At the same time, Acridine Orange is also known to stain the nucleus of the cells (green fluorescence). CLSM analyses of **DNA1@1-ART** NP-treated HeLa cells did not show any decrease in the fluorescence intensity when compared to the untreated control cells, suggesting that no lysosomal damage is caused by the NPs (Fig. 5c). This was further confirmed by using FACS analyses, which showed nearly the same MFI shifts of 65708 and 64344 for the control and **DNA1@1-ART** NP-treated cells, respectively (Fig. S16, ESI †). This is in accordance with our earlier observation that **DNA2@1** NPs undergo lysosomal escape. Interestingly, colocalization studies of mitochondria with MitoTracker deep red (red fluorescence) revealed excellent colocalization of the green fluorescence of **DNA2@1** NPs and the red fluorescence of MitoTracker deep red. This can be attributed to the disassembly of **DNA2@1** NPs inside the cytoplasm and the subsequent localization of **DNA2** (antisense DNA, G3139) in the mitochondria due to its high affinity for mitochondria (Fig. 5d). In addition, Cy3.5 is also known to have high affinity for mitochondria.⁴⁰ However, the binding of **DNA2** to the mitochondria did not cause any damage to the mitochondria or its membrane, which was confirmed using a tetramethylrhodamine methyl ester perchlorate (TMRM) assay.

TMRM exhibits orange fluorescence when accumulated in negatively charged polarized mitochondria. When the

mitochondrial membrane potential collapses due to apoptosis or metabolically stressed cells, TMRM reagent is dispersed throughout the cell cytosol, and the fluorescence intensity drops down dramatically. Interestingly, **DNA2@1** NP-treated HeLa cells did not show any decrease in the fluorescence from mitochondria when compared to untreated control cells, suggesting that no mitochondrial damage has occurred (Fig. 5e). This was further verified through FACS analyses, which revealed similar MFI shifts of 2894 and 2777 for the control and **DNA1@1-ART** NP-treated cells, respectively (Fig. S17, ESI †). Collectively these experiments conclude that after the lysosomal escape of **DNA2@1** NPs, they immediately undergo GSH-triggered disassembly, and release **DNA2** and Fe $^{2+}$ at the cytosol. Because of the mitochondria affinity and also due to the presence of Cy3.5, the antisense DNA (**DNA2**) gets accumulated at the mitochondria.

We next studied the generation of radical species by **DNA1@1** and **DNA1@1-ART** NPs inside the HeLa cells by using 2,7-dichlorofluorescein-diacetate (DCFH-DA) as the marker for radical species, which produces green fluorescent 2,7-dichlorofluorescein (DCF) upon radical detection. As shown in Fig. 6a, **DNA1@1-ART** NP-treated HeLa cells showed obviously stronger DCF green fluorescence than **DNA1@1** or **ART**-treated cells, indicating higher radical (both \cdot OH and carbon centered radicals) generation for **DNA1@1-ART** NP-treated cancer cells through Fenton and Fenton-like reactions, as explained previously. The corresponding






Fig. 6 (a) CLSM images of **ART**, **DNA1@1** and **DNA1@1-ART** NP-treated HeLa cells stained with DCFH-DA. (b) CLSM images of DCFH-DA stained and **DNA1@1-ART** NP-treated HeLa cells in the presence of Fe^{2+} chelator, 2,2'-bipyridyl.

FACS analyses showed MFI shifts of 473, 506, 2882 and 16691 for the control, **ART**, **DNA1@1** NPs and **DNA1@1-ART** NPs, respectively (Fig. S18, ESI[†]). This is in full agreement with the CLSM results. To further validate that the radical generation indeed occurs *via* Fe^{2+} -catalysed Fenton reactions, the cells were pre-incubated with a Fe^{2+} binding agent, 2,2'-bipyridyl and then treated with **DNA1@1-ART** NPs. As expected, a significant decrease in green fluorescence of DCF was observed when compared to the corresponding bipyridyl-untreated cells (FACS revealed MFI value of 626, Fig. S19, ESI[†]), which indicates that the intracellular radical production indeed occurs through the Fe^{2+} -catalysed cascade Fenton reactions (Fig. 6b).

The cytotoxicity of **DNA1@1-ART** NPs was evaluated using the MTT assay on HeLa cell lines. Before investigating the cytotoxicity of the **DNA1@1-ART** NPs, the cytotoxicity of its individual components was studied. Initially, HeLa cell lines were incubated with free **DNA1** for 24 h with varying concentrations in

the range of 50–1000 nM. Though **DNA1** is an antisense DNA and can potentially induce cell apoptosis, no significant cell death was observed in this case, and the cell viability remained more than 80% in the entire concentration range (Fig. 7a). This might be due to the cell impermeable nature of free oligonucleotides and hence **DNA1** is unable to induce any cell apoptosis. Subsequently, **ART** of different concentrations was incubated with HeLa cells for 24 h to assess the cytotoxicity of free **ART**. In this case as well, cell viability remains more than 60% even at a higher concentration of 250 μM , and this is very much expected due to the poor water solubility of **ART** in the physiological media (Fig. 7b). On the other hand, incubation of HeLa cells with **DNA1@1-ART** NPs showed reasonable cytotoxicity with a cell death of more than 75% (Fig. 7c). Though commendable cytotoxicity was achieved, the relatively reduced efficacy of the system can be attributed to the large size of the NPs, which hinders the efficient cellular internalization of the NPs. This suggests that the efficacy can be improved by reducing the size of the NPs. In order to validate the role of **DNA1** in the overall cytotoxicity of **DNA1@1-ART** NPs, we synthesized two other control NPs, **DNA3@1-ART** and **DNA3@1** NPs. In these cases, **DNA3** is a scrambled DNA with no therapeutic value. MTT analyses of both **DNA3@1-ART** and **DNA3@1** NPs revealed reduced cytotoxicity when compared to the corresponding **DNA1@1-ART** NPs. These results clearly support our hypothesis that the excellent cytotoxicity of **DNA1@1-ART** NPs is due to the combined effect of Fenton reactions and the gene therapeutic effect of **DNA1**. A comparison of the cytotoxicity of free **ART** with the corresponding **DNA1@1-ART** NPs revealed enhanced cytotoxicity for the latter in a dose-dependent manner (Fig. 7d). The reduced therapeutic efficacy of free **ART** must be due to the poor water solubility of **ART** and its water solubility is significantly improved when encapsulated inside **DNA1@1** NPs and hence exhibits increased therapeutic efficacy. The potential of




Fig. 7 Cell viability assay of HeLa cells (a) with varying concentrations of **DNA1** and (b) **ART**. (c) Comparison of cell viability of HeLa cells treated with **DNA3**, **DNA1**, **DNA3@1** NPs, **DNA3@1-ART** NPs and **DNA1@1-ART** NPs for 24 h incubation. (d) Comparison of cell viability of HeLa cells treated with different concentrations of **ART** for free **ART** and **DNA1@1-ART** NPs.






Fig. 8 (a) Calcein-AM/ethidium homodimer-1 live/dead cell assay of **DNA1@1-ART** NP-treated HeLa cells. (b) Annexin V-FITC/propidium iodide assay of **DNA1@1-ART** NP-treated HeLa cells.

DNA as a template to carry various metal ions for Fenton-like reaction for CDT application has been well demonstrated by several research groups.^{31–33} In these approaches, typically metal ions are released by the degradation of DNA and hence the therapeutic value of DNA is completely lost in these cases. On the other hand, in our approach, GSH-triggered cleavage of the disulfide bond of **1** causes the disassembly as well as activation of metal ions from their prodrug state to the active state, and hence the damage caused to DNA is minimized. In order to validate this hypothesis, NPs comprising Fe^{2+} and G3139 (**DNA1@Fe2+**) were synthesized by annealing of Fe^{2+} and G3139 in 1:50 molar ratio by following a literature procedure and characterized using various microscopic techniques.³¹ Comparison of cell viability of **DNA1@Fe2+** with **DNA1@1** NPs revealed enhanced cytotoxicity for **DNA1@1** NPs (Fig. S20, ESI[†]).

Finally, the cytotoxicity of **DNA1@1-ART** NPs was directly visualized by calcein-AM/ethidium homodimer-1 co-staining assay. For this purpose, HeLa cells were treated with **DNA1@1-ART** NPs and then stained with calcein-AM and ethidium homodimer-1 dyes for 24 h. Calcein-AM stains viable cells and gives green fluorescence, whereas ethidium homodimer-1 stains dead cells and gives red fluorescence. As shown in Fig. 8a, untreated HeLa cells (control) showed only calcein-AM staining and no ethidium homodimer-1 staining, indicating that all the cells are alive, as expected. On the

other hand, notable reduction in calcein-AM staining and significant dead cell staining by ethidium homodimer-1 were observed for **DNA1@1-ART** NP-treated cells. These results are unambiguous to demonstrate the effective killing of cancer cells by **DNA1@1-ART** NPs and are in full agreement with MTT analyses. Subsequently, an annexin V-FITC (AV)/propidium iodide (PI) assay was performed to gather better insight into the mechanism of cell death. Annexin V is a specific marker for apoptosis, which binds specifically to the exposed phosphatidylserine (PS) on the cell surface in the early-stage of apoptosis, and PI stains the nuclear chromatin during the late stage of apoptosis. As shown in Fig. 8b, **DNA1@1-ART** NP-treated cells exhibited strong green fluorescence from annexin V-FITC at the cell membrane and red fluorescence of PI from the nuclei indicating the late-stage apoptosis. These results suggest that the mechanism of cell death is apoptosis and is not following the necrosis pathway. This is further confirmed through the FACS analyses. For this, HeLa cells were treated with **DNA1@1-ART** NPs for 24 h and analysed by flow cytometry after staining with annexin V-FITC (AV)/propidium iodide (PI). As shown in Fig. S21 (ESI[†]), the number of apoptotic cells increased to 86.56% (including early apoptosis and late apoptosis). These results unequivocally conclude that the mechanism of cell death is indeed due to the apoptosis mechanism and not due to the necrotic pathway.

Conclusions

In summary, we have demonstrated a supramolecular strategy for the crafting of tumour microenvironment sensitive NPs composed of **ART**, ferrocene derivative **1** (GSH and redox-active) and **DNA1** (antisense DNA) *via* a single-step assembly process. The most remarkable feature of our design strategy is the GSH-triggered cascade reactions of the NPs inside the cancer cell in a cooperative fashion for synergistic cancer therapy. Cleavage of disulfide bonds of the NPs by the overexpressed GSH in the tumour microenvironment leads to the following cascade CDT reactions: (i) GSH-triggered uncaging of **1** releases amino ferrocene, which then undergoes reaction with endogenous H_2O_2 to produce $\cdot\text{OH}$ radicals and Fe^{3+} and (ii) the *in situ* reduction of Fe^{3+} by GSH to form Fe^{2+} and the subsequent Fe^{2+} -triggered cleavage of the peroxide bond of **ART** to form carbon-centered free radicals (H_2O_2 independent pathway). Furthermore, disassembly of the NPs releases **DNA1**, which downregulates the translation of Bcl-2 mRNA and thereby causes cell apoptosis. The enhanced therapeutic efficacy of our approach is attributed to the cooperative cascade CDT and antisense therapy. We hope the simple yet efficient supramolecular approach demonstrated here may encourage other researchers to design stimuli-responsive multifunctional nano-systems for combination cancer therapy.

Author contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.



Conflicts of interest

There are no conflicts to declare.

Acknowledgements

Financial support from DBT (BT/PR30172/NNT/28/1593/-2018) is gratefully acknowledged. The help of Sarika Mohan S. is acknowledged for the FACS analyses.

References

- 1 Z. Tang, Y. Liu, M. He and W. Bu, Chemodynamic Therapy: Tumour Microenvironment-Mediated Fenton and Fenton-like Reactions, *Angew. Chem., Int. Ed.*, 2019, **58**, 946–956.
- 2 E. Hwang and H. S. Jung, Metal-organic complex-based chemodynamic therapy agents for cancer therapy, *Chem. Commun.*, 2020, **56**, 8332–8341.
- 3 C. Cao, X. Wang, N. Yang, X. Song and X. Dong, Recent advances of cancer chemodynamic therapy based on Fenton/Fenton-like chemistry, *Chem. Sci.*, 2022, **13**, 863–889.
- 4 H. Lin, Y. Chen and J. Shi, Nanoparticle-triggered in situ catalytic chemical reactions for tumour-specific therapy, *Chem. Soc. Rev.*, 2018, **47**, 1938–1958.
- 5 Y. Li, W. Xiu, K. Yang, Q. Wen, L. Yuwen, Z. Luo, X. Liu, D. Yang, X. Xie and L. Wang, A multifunctional Fenton nanoagent for microenvironment-selective anti-biofilm and anti-inflammatory therapy, *Mater. Horizons*, 2021, **8**, 1264–1271.
- 6 J. Tan, H. Li, X. Hu, R. Abdullah, S. Xie, L. Zhang, M. Zhao, Q. Luo, Y. Li, Z. Sun, Q. Yuan and W. Tan, Size-Tunable Assemblies Based on Ferrocene-Containing DNA Polymers for Spatially Uniform Penetration, *Chem*, 2019, **5**, 1775–1792.
- 7 X. Li, Q. Zhou, A. A-W. M. M. Japir, D. Dutta, N. Lu and Z. Ge, Protein-Delivering Nanocomplexes with Fenton Reaction-Triggered Cargo Release to Boost Cancer Immunotherapy, *ACS Nano*, 2022, **16**, 14982–14999.
- 8 P. Ma, H. Xiao, C. Yu, J. Liu, Z. Cheng, H. Song, X. Zhang, C. Li, J. Wang, Z. Gu and J. Lin, Enhanced Cisplatin Chemotherapy by Iron Oxide Nanocarrier-Mediated Generation of Highly Toxic Reactive Oxygen Species, *Nano Lett.*, 2017, **17**, 928–937.
- 9 Q. Chen, J. Zhou, Z. Chen, Q. Luo, J. Xu and G. Song, Tumor-Specific Expansion of Oxidative Stress by Glutathione Depletion and Use of a Fenton Nanoagent for Enhanced Chemodynamic Therapy, *ACS Appl. Mater. Interfaces*, 2019, **11**, 30551–30565.
- 10 L.-S. Lin, J. Song, L. Song, K. Ke, Y. Liu, Z. Zhou, Z. Shen, J. Li, Z. Yang, W. Tang, G. Niu, H.-H. Yang and X. Chen, Simultaneous Fenton-like Ion Delivery and Glutathione Depletion by MnO₂-Based Nanoagent to Enhance Chemodynamic Therapy, *Angew. Chem., Int. Ed.*, 2018, **57**, 4902–4906.
- 11 J. Fu, Y. Shao, L. Wang and Y. Zhu, Lysosome-controlled efficient ROS overproduction against cancer cells with a high pH-responsive catalytic nanosystem, *Nanoscale*, 2015, **7**, 7275–7283.
- 12 Y. He, A. del Valle, Y. Qian and Y.-F. Huang, Near infrared light-mediated enhancement of reactive oxygen species generation through electron transfer from graphene oxide to iron hydroxide/oxide, *Nanoscale*, 2017, **9**, 1559–1566.
- 13 G. Lan, K. Ni, Z. Xu, S. S. Veroneau, Y. Song and W. Lin, Nanoscale Metal-Organic Framework Overcomes Hypoxia for Photodynamic Therapy Primed Cancer Immunotherapy, *J. Am. Chem. Soc.*, 2018, **140**, 5670–5673.
- 14 X. Zhong, X. Wang, L. Cheng, Y. Tang, G. Zhan, F. Gong, R. Zhang, J. Hu, Z. Liu and X. Yang, GSH-Depleted PtCu₃ Nanocages for Chemodynamic-Enhanced Sonodynamic Cancer Therapy, *Adv. Funct. Mater.*, 2020, **30**, 1907954.
- 15 L. V. Nair, S. S. Nazeer, R. S. Jayasree and A. Ajayaghosh, Fluorescence Imaging Assisted Photodynamic Therapy Using Photosensitizer-Linked Gold Quantum Clusters, *ACS Nano*, 2015, **9**, 5825–5832.
- 16 C. Tong, T. Liu, V. Saez Talens, W. E. M. Noteborn, T. H. Sharp, M. M. R. M. Hendrix, I. K. Voets, C. L. Mummery, V. V. Orlova and R. E. Kiely, Squaramide-Based Supramolecular Materials for Three-Dimensional Cell Culture of Human Induced Pluripotent Stem Cells and Their Derivatives, *Biomacromolecules*, 2018, **19**, 1091–1099.
- 17 W. Xuan, Y. Xia, T. Li, L. Wang, Y. Liu and W. Tan, Molecular Self-Assembly of Bioorthogonal Aptamer-Prodrug Conjugate Micelles for Hydrogen Peroxide and pH-Independent Cancer Chemodynamic Therapy, *J. Am. Chem. Soc.*, 2020, **142**, 937–944.
- 18 P. Ji, H. Huang, S. Yuan, L. Wang, S. Wang, Y. Chen, N. Feng, H. Veroniaina, Z. Wu, Z. Wu and X. Qi, ROS-Mediated Apoptosis and Anticancer Effect Achieved by Artesunate and Auxiliary Fe(II) Released from Ferri-ferrous Oxide-Containing Recombinant Apoferritin, *Adv. Healthc. Mater.*, 2019, **8**, 1900911.
- 19 X. Wan, H. Zhong, W. Pan, Y. Li, Y. Chen, N. Li and B. Tang, Programmed Release of Dihydroartemisinin for Synergistic Cancer Therapy Using a CaCO₃ Mineralized Metal-Organic Framework, *Angew. Chem., Int. Ed.*, 2019, **58**, 14134–14139.
- 20 L. Shao, T. Hu, X. Fan, X. Wu, F. Zhou, B. Chen, S. Tan, H. Xu, A. Pan, S. Liang and Y. He, Intelligent Nanoplat-form with Multi Therapeutic Modalities for Synergistic Cancer Therapy, *ACS Appl. Mater. Interfaces*, 2022, **14**, 13122–13135.
- 21 Y. Luo, X. Sun, L. Huang, J. Yan, B.-Y. Yu and J. Tian, Artemisinin-Based Smart Nanomedicines with Self-Supply of Ferrous Ion to Enhance Oxidative Stress for Specific and Efficient Cancer Treatment, *ACS Appl. Mater. Interfaces*, 2019, **11**, 29490–29497.
- 22 H. Pei, N. Lu, Y. Wen, S. Song, Y. Liu, H. Yan and C. Fan, A DNA Nanostructure-based Biomolecular Probe Carrier Platform for Electrochemical Biosensing, *Adv. Mater.*, 2010, **22**, 4754–4758.
- 23 A. T. Veetil, K. Chakraborty, K. Xiao, M. R. Minter, S. S. Sisodia and Y. Krishnan, Cell-targetable DNA nanocapsules for spatiotemporal release of caged bioactive small molecules, *Nat. Nanotechnol.*, 2017, **12**, 1183–1189.
- 24 S. Walia, V. Morya, A. Gangrade, S. Naskar, A. Guduru Teja, S. Dalvi, P. K. Maiti, C. Ghoroi and D. Bhatia, Designer DNA



- Hydrogels Stimulate 3D Cell Invasion by Enhanced Receptor Expression and Membrane Endocytosis, *ACS Biomater. Sci. Eng.*, 2021, **7**, 5933–5942.
- 25 S. Kadekar, G. N. Nawale, V. K. Rangasami, V. Le Joncour, P. Laakkonen, J. Hilborn, O. P. Varghese and O. P. Oommen, Redox responsive Pluronic micelle mediated delivery of functional siRNA: a modular nano-assembly for targeted delivery, *Biomater. Sci.*, 2021, **9**, 3939–3944.
 - 26 H. V. P. Thelu, S. Atchimnaidu, D. Perumal, K. S. Harikrishnan, S. Vijayan and R. Varghese, Self-Assembly of an Aptamer-Decorated, DNA-Protein Hybrid Nanogel: A Biocompatible Nanocarrier for Targeted Cancer Therapy, *ACS Appl. Bio Mater.*, 2019, **2**, 5227–5234.
 - 27 S. Atchimnaidu, D. Perumal, K. S. Harikrishnan, H. V. P. Thelu and R. Varghese, Phototheranostic DNA micelles from the self-assembly of DNA-BODIPY amphiphiles for the thermal ablation of cancer cells, *Nanoscale*, 2020, **12**, 11858–11862.
 - 28 D. Bousmail, L. Amrein, J. J. Fakhoury, H. H. Fakih, J. C. C. Hsu, L. Panasci and H. F. Sleiman, *Chem. Sci.*, 2017, **8**, 6218–6229.
 - 29 J. Liu, L. Song, S. Liu, Q. Jiang, Q. Liu, N. Li, Z.-G. Wang and B. Ding, A DNA-Based Nanocarrier for Efficient Gene Delivery and Combined Cancer Therapy, *Nano Lett.*, 2018, **18**, 3328–3334.
 - 30 H. Shi, X. Ye, X. He, K. Wang, W. Cui, D. He, D. Li and X. Jia, Au@Ag/Au nanoparticles assembled with activatable aptamer probes as smart “nano-doctors” for image-guided cancer thermotherapy, *Nanoscale*, 2014, **6**, 8754–8761.
 - 31 Y. Yang, W. Zhu, L. Feng, Y. Chao, X. Yi, Z. Dong, K. Yang, W. Tan, Z. Liu and M. Chen, G-Quadruplex-Based Nanoscale Coordination Polymers to Modulate Tumor Hypoxia and Achieve Nuclear-Targeted Drug Delivery for Enhanced Photodynamic Therapy, *Nano Lett.*, 2018, **18**, 6867–6875.
 - 32 Q. Zhang, Q. Jiang, N. Li, L. Dai, Q. Liu, L. Song, J. Wang, Y. Li, J. Tian, B. Ding and Y. Du, DNA origami as an in vivo drug delivery vehicle for cancer therapy, *ACS Nano*, 2014, **8**, 6633–6643.
 - 33 B. Liu, F. Hu, J. Zhang, C. Wang and L. Li, A Biomimetic Coordination Nanoplatfor for Controlled Encapsulation and Delivery of Drug–Gene Combinations, *Angew. Chem., Int. Ed.*, 2019, **58**, 8804–8808.
 - 34 L. Lin, J. Yu, H. Lu, Z. Wei, Z. Chao, Z. Wang, W. Wu, H. Jiang and L. Tian, Mn–DNA coordination of nanoparticles for efficient chemodynamic therapy, *Chem. Commun.*, 2021, **57**, 1734–1737.
 - 35 C. Liu, Y. Chen, J. Zhao, Y. Wang, Y. Shao, Z. Gu, L. Li and Y. Zhao, Self-Assembly of Copper–DNAzyme Nanohybrids for Dual-Catalytic Tumor Therapy, *Angew. Chem., Int. Ed.*, 2021, **60**, 14324–14328.
 - 36 H. Hagen, P. Marzenell, E. Jentzsch, F. Wenz, M. R. Veldwijk and A. Mokhir, Aminoferrocene-based prodrugs activated by reactive oxygen species, *J. Med. Chem.*, 2012, **55**, 924–934.
 - 37 S. Lei, J. Chen, K. Zeng, M. Wang and X. Ge, Visual dual chemodynamic/photothermal therapeutic nanoplatfor based on superoxide dismutase plus Prussian blue, *Nano Res.*, 2019, **12**, 1071–1082.
 - 38 S. E. Lehman, A. S. Morris, P. S. Mueller, A. K. Salem, V. H. Grassian and S. C. Larsen, Silica nanoparticle-generated ROS as a predictor of cellular toxicity: mechanistic insights and safety by design, *Environ. Sci.: Nano*, 2016, **3**, 56–66.
 - 39 H. Hou, X. Huang, G. Wei, F. Xu, Y. Wang and S. Zhou, Fenton Reaction-Assisted Photodynamic Therapy for Cancer with Multifunctional Magnetic Nanoparticles, *ACS Appl. Mater. Interfaces*, 2019, **11**, 29579–29592.
 - 40 J. Liu, L. Yang, C. Xue, G. Huang, S. Chen, J. Zheng and R. Yang, Reductase and Light Programmatical Gated DNA Nanodevice for Spatiotemporally Controlled Imaging of Biomolecules in Subcellular Organelles under Hypoxic Conditions, *ACS Appl. Mater. Interfaces*, 2021, **13**, 33894–33904.

